View DividendRafarma Pharmaceuticals 경영진경영진 기준 점검 1/4현재 CEO에 대한 정보가 충분하지 않습니다.핵심 정보 최고경영자n/a총 보수CEO 급여 비율n/aCEO 재임 기간no dataCEO 지분 보유율n/a경영진 평균 재임 기간데이터 없음이사회 평균 재임 기간6.1yrs최근 경영진 업데이트공시 • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.모든 업데이트 보기Recent updates공시 • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.공시 • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.공시 • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.공시 • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.공시 • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.공시 • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.CEORafarma Pharmaceuticals에는 CEO가 없거나 해당 데이터가 없습니다.이사회 구성원이름직위재임 기간보수지분Sergey BrusnitsinChief Financial Officer and Directorno data데이터 없음데이터 없음Alexander AgeevSecretaryno data데이터 없음데이터 없음Bruno HornDirector11.8yrs데이터 없음데이터 없음Sreco BojtDirectorno data데이터 없음데이터 없음Vladislav LaskavyMember of the Advisory Board6.1yrs데이터 없음데이터 없음Ilya ShpurovChairman of the Board5.7yrs데이터 없음데이터 없음더 보기6.1yrs평균 재임 기간경험이 풍부한 이사회: RAFA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.1 년).View Ownership기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:44종가2026/05/22 00:00수익2012/03/31연간 수익2012/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rafarma Pharmaceuticals, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.
공시 • Jan 31Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of UzbekistanRafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan.
공시 • Dec 17Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals IncVaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc.
공시 • Dec 02Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of MalaysiaRafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide.
공시 • Oct 20R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group. R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020.
공시 • Sep 19Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the BoardRafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.
공시 • Aug 06R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA).R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.